TYRX, Inc has announced the commercial release of AIGISRx Flat. AIGISRx is an antibacterial product providing protection against infections that are associated with implanted pacemakers and defibrillators. Much like the AIGISRx Envelope, the Flat deliver anti-microbial agents, rifampin and minocycline. It has been shown to reduce infection caused by organisms that represent a majority of infections reported in cardiac rhythm management device related endocarditis such as superbugs or MRSA. It also offers the implanting physician with additional flexibility in the application of lifesaving devices.
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.
TYRX, Inc., an ISO 9001:2000 and ISO 13485:2003 certified medical device manufacturer, commercializes implantable combination drug/device products focused on infection control. TYRX is deploying its capabilities across a broad range of implantable medical devices and is positioned to be the innovative leader in this area. In 2008 TYRX raised $25 million in a venture capital financing led by Clarus Ventures and co-led by Pappas Ventures.
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
Follow us on Twitter: http://www.Twitter.com/topbestps
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
